Core Viewpoint - Anteris Technologies Global Corp. is actively participating in two major healthcare conferences, showcasing its commitment to advancing medical devices for heart function restoration [1][4]. Group 1: Conference Details - Anteris will present at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, featuring a fireside chat with analyst Joshua Jennings [2]. - The Barclays 28th Annual Healthcare Conference will take place on March 10, 2026, with a fireside chat led by analyst Matt Miksic [3]. - Both conferences will include 1x1 meetings and will be accessible via webcasts, which will be archived for up to 90 days [2][3]. Group 2: Company Overview - Anteris Technologies is a global structural heart company focused on designing and commercializing innovative medical devices [4]. - The company is headquartered in Australia and has a significant operational presence in Minneapolis, USA, emphasizing a science-driven approach [4]. - Anteris' lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [5].

Core Viewpoint - Anteris Technologies Global Corp. announced a significant capital raise, leading to a 52.17% increase in share price during after-hours trading, reaching $8.75, following a regular session close of $5.75, which was up 12.52% [1]. Group 1: Capital Raise Details - The company plans to conduct a $200 million underwritten public offering of common stock, with underwriters having a 30-day option to purchase an additional $30 million in shares at the offering price [2]. - Anteris has also agreed to sell up to $90 million in common stock to Medtronic plc through a private placement, with Medtronic set to acquire between 16% and 19.99% of shares outstanding after the public offering [3]. Group 2: Use of Proceeds - Proceeds from the capital raise will be utilized to support the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis, as well as to expand manufacturing capacity and development for v2vmedtech, inc. [5]. Group 3: Trading Metrics and Analysis - Anteris has a market capitalization of $236.89 million, with its stock trading within a 52-week range of $2.34 to $8.79. Over the past 12 months, the stock has seen a decline of 2.21%, indicating ongoing challenges for the company [6]. - The stock is currently positioned at 52.9% of its 52-week range, nearing yearly highs, and has a Relative Strength Index (RSI) of 66.01, suggesting a positive price trend across all time frames [6][7].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].